OBJECTIVES: To investigate the relationship between lysosome-associated protein transmembrane-4b-35 (LAPTM4B-35) and the clinicopathological features and prognosis of pancreatic carcinoma. METHODS: The level of LAPTM4B-35 protein was determined by semiquantitative immunohistochemistry in pancreatic carcinoma specimens. The relationship between LAPTM4B-35 level and prognosis was determined using univariate and multivariate analyses. RESULTS: A total of 98 patient samples were included. The presence of LAPTM4B-35 protein was confirmed in 77/98 (78.6%) patients and was significantly associated with tumour stage, degree of differentiation and pathological staging of pancreatic carcinoma after primary surgery. Patients with high LAPTM4B-35 levels had a poorer overall survival compared with patients with lower levels. Multivariate analysis showed that LAPTM4B-35 was an independent prognostic factor for overall survival. CONCLUSIONS: LAPTM4B-35 was found to be present at high levels in a large proportion of patients with pancreatic carcinoma, and was closely related to disease progression and poor prognosis. LAPTM4B-35 may represent a new molecular target for the clinical evaluation and treatment of pancreatic carcinoma.
Introduction
Pancreatic carcinoma is the fourth most common cause of cancer-related death worldwide, 1 mainly on account of the aggressive behaviour and high metastatic potential of this tumour. 2 The estimated incidence of pancreatic carcinoma reached 38 000 in North America in 2008, with disease-specific mortality equalling its incidence. 3, 4 Pancreatic carcinoma is not responsive to chemotherapy or radiotherapy and overall 5-year survival is less than the G Zhang, Y Liang, Y Huang et al. LAPTM4B-35 protein in pancreatic cancer median survival after diagnosis, which is approximately 6 months. 5 Although operative resection remains the most effective treatment for pancreatic carcinoma, adjuvant or neoadjuvant radiotherapy has been used increasingly (in combination with resection) to reduce the risk of tumour metastasis or recurrence. 6, 7 Reasons for the high disease-specific mortality associated with pancreatic carcinoma include the absence of early disease symptoms 8 and the high propensity for local invasion of adjacent structures, perineural invasion and early lymph node and liver metastases. 9 Lymph node metastasis and blood vessel invasion are definitive prognostic factors after surgical resection. 10 Lysosomal protein transmembrane-4β (LAPTM4B) is a hepatocellular carcinoma (HCC)-associated gene that was originally cloned and identified at Peking University. 11 LAPTM4B, which maps to chromosome 8q22 and contains seven exons, is a member of the mammalian 4-tetratransmembrane-spanning protein superfamily. Studies have shown that the LAPTM4B gene encodes two proteins with molecular weights of 35 and 24 kDa, and that its activity is elevated in several human cancers. 12 -19 The expression of LAPTM4B in pancreatic cancer and its role in disease progression are, however, unknown.
The present retrospective study investigated the level of LAPTM4B-35 protein in pancreatic carcinoma tissue samples taken from patients undergoing surgical resection, and assessed its relationship to the clinical and pathological features of the disease. The prognostic significance of LAPTM4B-35 was also evaluated using univariate and multivariate analyses. 20 Follow-up of patients for the survival analysis was completed in December 2011.
Patients and methods

STUDY POPULATION
The study protocol was approved by the Research Ethics Committee of the Affiliated Union Hospital of Fujian Medical University. All patients or their families provided written informed consent.
IMMUNOHISTOCHEMICAL STAINING AND EVALUATION
The level of LAPTM4B-35 protein was evaluated immunohistochemically in paraffin-embedded tissue specimens. Surgical specimens were fixed in 10% formalin, embedded in paraffin and 4-µm thick sections were cut. Tissue blocks were deparaffinized in xylene and rehydrated using a graded series of ethanol. For antigen retrieval, the sections in 0.01 M sodium citrate buffer (pH 6.0) were heated in a microwave oven at 95°C for 30 min. The G Zhang, Y Liang, Y Huang et al.
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endogenous peroxidase activity of the specimens was blocked by incubation in 3% hydrogen peroxide and methanol for 10 min at room temperature. After incubation in 1% bovine serum albumin for 30 min at room temperature to block nonspecific reactions, the sections were incubated with purified anti-LAPTM4B-35 polyclonal antibody (1:100 dilution; kindly provided by Professor Rou-Li Zhou, Department of Cell Biology, Peking University Health Science Centre, Beijing, China) at 4°C for 16 h. 21 Immunoreactivity was visualized using the PV 9000 two-step immunohistological staining kit (GBI Labs, Mukilteo, WA, USA) and 3,3′-diaminobenzidine tetrahydrochloride (Zhongshan Jinqiao, Beijing, China) following the manufacturers' instructions. The sections were rinsed three times for 9 min in 0.01 M phosphate-buffered saline (pH 7.3) at each stage of the experiment. As a negative control, the primary antibody was replaced with normal rabbit immunoglobulin G at an appropriate dilution. Sections were counterstained with haematoxylin, dehydrated and embedded in neutral balsam.
The level of LAPTM4B-35 protein was classified semiquantitatively by a combined scoring system, consisting of scores for the proportion (percentage) of positively stained tumour cells (0, < 5%; 1, 5 -50%; 2, > 50% stained cells) 22 and staining intensity (0, no staining or weak staining; 1, moderate staining; 2, strong staining). The final staining score was obtained by adding together the scores for the proportion of positively stained cells and staining intensity. Scores for LAPTM4B-35 protein levels were defined as 'low' if the sum of the combined scores was 0 -2, or 'high' if the combined sum was 3 -4. For each section, at least three different tumour areas were evaluated and the mean value was taken as the final score. Two observers who were blinded to prior clinical information evaluated the staining results independently and co-observed to reach consensus when their first evaluations were divergent.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® statistical software, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The χ 2test was used to compare differences in categorical variables. Cumulative survival was assessed using the Kaplan-Meier method and between-group differences were analysed using the log-rank test. Cox regression (proportional hazards model) was adopted for multivariate analysis of prognostic factors. A P-value < 0.05 was considered to be statistically significant.
Results
This study included 98 patients (median age 57 years; range 23 -80 years). Their clinicopathological characteristics are shown in Table 1 . None of the patients died during their postoperative hospital stay following surgical resection. Follow-up ranged between 3 and 65 months (median 15 months). Up until 31 December 2011, 92 patients had died due to progression of pancreatic carcinoma. Survival of the remaining six patients ranged between 14 and 65 months.
Immunohistochemistry analysis showed that tissue samples from 77/98 patients (78.6%) had high levels of LAPTM4B-35 protein. Representative images of pancreatic carcinoma samples with different levels of LAPTM4B-35 immunostaining are shown in Fig. 1 . High LAPTM4B-35 levels were significantly associated with tumour stage (P = 0.009), degree of differentiation (P = 0.002) and pathological stage of pancreatic carcinoma (P < 0.001) ( Table  2 ; log-rank value 23.231; P < 0.001). The overall survival period for patients with low LAPTM4B-35 staining was significantly longer than that for patients with high LAPTM4B-35 staining ( Fig. 2 ; P < 0.001).
Univariate analysis revealed that TNM stage, degree of differentiation, pathological stage, vascular invasion and LAPTM4B-35 level all significantly affected the survival of patients with pancreatic carcinoma ( Table 2 ; P < 0.001 all comparisons). Multivariate analysis demonstrated that LAPTM4B-35 was an independent prognostic marker for overall survival (Table 2 ; relative risk -1.248; 95% confidence interval 0.145, 0.567; P < 0.001). Degree of differentiation (P = 0.044), pathological stage (P = 0.009) and node stage (P = 0.015) also independently predicted overall survival ( Table 2 ).
Discussion
Pancreatic carcinoma is a complex and heterogeneous disease involving numerous gene deletions, mutations and amplifications. 23 Disease development is related to alterations in a group of genes involved in specific pathways and processes, 21 meaning early diagnosis and treatment are difficult. The 5-year survival rate for pancreatic carcinoma is among the lowest of all malignancies, at only 5%. 5 Smoking is the only confirmed environmental risk factor, although diabetes mellitus, a high-cholesterol Protein levels were classified semiquantitatively by a combined scoring system consisting of the scores for the proportion of positively stained tumour cells (0, < 5%; 1, 5 -50%; 2, > 50% stained cells) 22 and staining intensity (0, no staining or weak staining; 1, moderate staining; 2, strong staining) and by adding together the two scores. 24 and diseases caused by CDKN2A gene mutations (which encode cyclin-dependent kinase inhibitor 2A), may also increase the risk of pancreatic cancer. 25 Markers for pancreatic cancer have been identified; serum CA19-9 is regarded as a reliable test for the detection of pancreatobiliary malignancy but does not reliably detect early, small, pancreatic cancers. 26 As far as we are aware, the present study is the first to demonstrate a relationship between the clinicopathological characteristics of pancreatic carcinoma and the prognostic significance of LAPTM4B-35 protein through semiquantitative immunohisto chemistry. LAPTM4B-35 protein was present in a large percentage of pancreatic carcinoma tissue samples and high LAPTM4B-35 staining was significantly correlated with tumour stage, degree of differentiation and pathological stage, but not with age, gender, metastasis or node stage, tumour location vascular invasion or serum CA19-9 level. The findings indicate that LAPTM4B-35 may be an independent prognostic factor in pancreatic carcinoma. Furthermore, patients with high LAPTM4B-35 staining had significantly poorer overall survival compared with patients with low LAPTM4B-35 staining, suggesting that LAPTM4B-35 may be extensively activated in pancreatic carcinoma and may play an important role in carcinogenesis and tumour progression. Multivariate analysis showed that LAPTM4B-35 was an independent prognostic marker for the overall survival of patients with pancreatic carcinoma.
Studies have shown that LAPTM4B-35 promotes cell growth and proliferation by upregulating several cell-cycle regulators, such as cyclin D 1 and E, and by activating several proto-oncogenes including c-myc, cjun and c-fos, and the phosphatidylinositol 3-kinase/Akt signalling pathway. 11,22,27 -31 In vivo and in vitro experiments have also shown that upregulation of LAPTM4B-35 in HepG2 and Bel7402 cells promotes the proliferation, migration and invasion of HCC, and that the use of antisense oligonucleotides against LAPTM4B suppresses growth and metastasis. 31 Studies have shown that upregulation of LAPTM4B-35 plays a critical role in cellular transformation, tumorigenesis and metastasis progression of several human malignancies including HCC, endometrial carcinoma, ovarian carcinoma, gallbladder carcinoma, cervical cancer and extrahepatic cholangiocarcinoma. 12 -14,16,21,32 The present study also confirmed that LAPTM4B-35 may affect carcinogenesis and cancer phenotypes, indicating that LAPTM4B-35 could represent a new target for the treatment of pancreatic carcinoma.
In summary, LAPTM4B-35 is present at high levels in a large proportion of patients with pancreatic carcinoma and is closely related to disease progression and poor prognosis. LAPTM4B-35 was found to be an independent prognostic marker of pancreatic carcinoma, suggesting that it may have potential as a new molecular target for the clinical evaluation and treatment of this disease.
